Company: OFIX
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026066
Chunk: 272

Company: Orthofix Medical Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 7
Chunk 272
---
165,927

    5.5
    %

    5.5
    %

    152.4
    %

    152.4
    %

    Global Spine

    675,314

    631,319

    353,174

    7.0
    %

    7.0
    %

    78.8
    %

    78.7
    %

    Global Orthopedics

    124,177

    115,322

    107,539

    7.7
    %

    7.9
    %

    7.2
    %

    5.2
    %

    Net sales
     
    $
    799,491

    $
    746,641

    $
    460,713

    7.1
    %

    7.1
    %

    62.1
    %

    61.6
    %

Global Spine

Global Spine offers the following products categories:

-Bone Growth Therapies, which manufactures, distributes, sells, and provides support services for market-leading devices used adjunctively in high-risk spinal fusion procedures and to treat both nonunion and acute fractures in the orthopedic space. Bone Growth Therapies uses distributors and a direct sales channel to sell its devices and provide associated support services to hospitals, healthcare providers, and patients in the U.S. 

-Spinal Implants, Biologics, and Enabling Technologies is comprised of a broad portfolio of spine fixation and motion preservation implant products used in surgical procedures of the spine, one of the most comprehensive biologics portfolios in both the demineralized bone matrix and cellular allograft market segments, and image-guided surgical solutions to facilitate degenerative, minimally invasive, and complex surgical procedures. Spinal Implants, Biologics, and Enabling Technologies products are sold through a network of distributors and sales representatives to hospitals and healthcare providers on a global basis for Spinal Implants and Enabling Technologies, primarily within the U.S. for Biologics.

2024 Compared to 2023

Net sales increased $44.0 million or 7.0%

•Bone Growth Therapies net sales increased $20.9 million, or 9.8%, driven by (i) an increase in gross order volumes from our continued investment in our direct sales channels for both the spine and fracture markets, (